This paper is a lale workup - viral dynamics analysis- of the Hepex-B trials that were initiated by
XTL, a company based in Israel. Hepex B is a double human monoclonal AB where both antibodies bind to the surface antigen with exceptional high affinity.
Since it is a human monoclonal, no antibodies to the antibody are expected to occur.Thus long term therapy is possible.
The trial used patients with a relatively low HbSAg titer, chronic HBV.